BioCentury | Feb 9, 2011
Financial News

Israel's RedHill prices IPO

...a minimum price of NIS305. The offering was underwritten by Poalim IBI; Apex; Excellence Nessuah; Meitav...
BioCentury | Jun 14, 2010
Financial News

Aposense completes IPO

...concurrent private with Leumi Partners and existing investors. Leumi Partners; Clal Finance; Menorah; Excellence; and Meitav...
BioCentury | Jun 14, 2010
Finance

IPO watch

...to radiation therapy. Data are expected in 1H11. Leumi Partners; Clal Finance; Menorah; Excellence; and Meitav...
BioCentury | Jun 8, 2010
Financial News

Aposense prices IPO

...and existing investors participated in the private placement. Leumi Partners; Clal Finance; Menorah; Excellence; and Meitav...
BioCentury | Aug 24, 2009
Finance

Ebb & Flow

...company also is supported by the Chief Scientist's Office in Israel. Clal Finance; Rosario; and Meitav...
BioCentury | Aug 24, 2009
Financial News

D-Pharm completes IPO

...million) Shares: 1.7 million Price: NIS16.63 Shares after offering: 13.7 million Underwriters: Clal Finance; Rosario; Meitav WIR...
BioCentury | Aug 18, 2009
Financial News

D-Pharm raises $22.4 million

...NIS16.63 price, the company is valued at NIS227 million ($59.5 million). Clal Finance; Rosario; and Meitav...
Items per page:
1 - 7 of 7
BioCentury | Feb 9, 2011
Financial News

Israel's RedHill prices IPO

...a minimum price of NIS305. The offering was underwritten by Poalim IBI; Apex; Excellence Nessuah; Meitav...
BioCentury | Jun 14, 2010
Financial News

Aposense completes IPO

...concurrent private with Leumi Partners and existing investors. Leumi Partners; Clal Finance; Menorah; Excellence; and Meitav...
BioCentury | Jun 14, 2010
Finance

IPO watch

...to radiation therapy. Data are expected in 1H11. Leumi Partners; Clal Finance; Menorah; Excellence; and Meitav...
BioCentury | Jun 8, 2010
Financial News

Aposense prices IPO

...and existing investors participated in the private placement. Leumi Partners; Clal Finance; Menorah; Excellence; and Meitav...
BioCentury | Aug 24, 2009
Finance

Ebb & Flow

...company also is supported by the Chief Scientist's Office in Israel. Clal Finance; Rosario; and Meitav...
BioCentury | Aug 24, 2009
Financial News

D-Pharm completes IPO

...million) Shares: 1.7 million Price: NIS16.63 Shares after offering: 13.7 million Underwriters: Clal Finance; Rosario; Meitav WIR...
BioCentury | Aug 18, 2009
Financial News

D-Pharm raises $22.4 million

...NIS16.63 price, the company is valued at NIS227 million ($59.5 million). Clal Finance; Rosario; and Meitav...
Items per page:
1 - 7 of 7